ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
3
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
3,033
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy
Author(s):
M Breccia
,
F Lo-Coco
,
F Lo Coco
Publication date:
2011
Journal:
Expert Opin Biol Ther
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Tobacco Prevention & Cessation
Data availability:
ScienceOpen disciplines:
Medicine
,
Health & Social care
Comments
Comment on this article
Sign in to comment
Similar content
3,033
Successful combination of anti-CD33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia.
Authors:
Mathias Hänel
,
Christian Thiede
,
Anett Helwig
…
Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells
Authors:
RB Walter
,
BW Raden
,
TC Hong
…
PCN23 GEMTUZUMAB OZOGAMICIN PLUS STANDARD CHEMOTHERAPY CARRIES A COMPARABLE BURDEN OF HOSPITALIZATION COMPARED WITH STANDARD CHEMOTHERAPY ALONE IN ACUTE MYELOID LEUKEMIA
Authors:
S. Sikirica
,
T.A. Russell-Smith
,
V.L. Welch
…
See all similar
Cited by
1
The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin
Authors:
Maurizio Cianfriglia
See all cited by